Review article: Non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 8, 2003, Pages 977-986

  Alba, L M ^a   Lindor, K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIODARONE; BETAINE; CHLOROQUINE; CLOFIBRATE; CORTICOSTEROID; DILTIAZEM; ESTROGEN; GEMFIBROZIL; METFORMIN; NIFEDIPINE; PENTOXIFYLLINE; PERHEXILINE MALEATE; SILYMARIN; TAMOXIFEN; TETRACYCLINE; THIAZOLE DERIVATIVE; THIAZOLIDENEDIONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FATTY LIVER; GASTROINTESTINAL SURGERY; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER TRANSPLANTATION; LOW CALORY DIET; NON ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEATOSIS; SURGICAL TECHNIQUE; TREATMENT INDICATION; WEIGHT REDUCTION;

ALCOHOL DRINKING; BIOPSY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY LIVER; HUMANS; HYPERLIPIDEMIAS; LIVER DISEASES; LIVER TRANSPLANTATION; OBESITY;

EID: 0038707252     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01493.x     Document Type: Review

References (80)

1. Ludwig J, Viggiano TR, McGili DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-6.
3. Teli MR, James OFW, Burr JA, Bennet MK, Day CP. The natural history of nonalcoholic fatty liver: a follow up study. Hepatology 1995; 22: 1714-9.
4. Lee RG. Non alcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989; 20: 594-8.
5. Powell EE, Cooksley GE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
6. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease. A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
8. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
9. Diehl AM, Goodman Z, Ishak G. Alcohol like liver disease in nonalcoholics. A clinical and histological comparison with alcohol induced liver injury. Gastroenterology 1988; 95: 1056-62.
10. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in the general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-9.
11. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 1998; 22: 222-6.
12. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-51.
13. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. Dig Dis Sci 1995; 4: 2002-9.
14. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1438-2.
15. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
16. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349-55.
17. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-7.
18. Sorbi D, Boyton J, Lindor KD. The ratio of aspartate amino-transferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-22.
19. Fletcher LM, Kwoh-Gain L, Powell E, et al. Markers of chronic alcohol ingestion in non-alcoholic steatohepatitis: an aid to diagnosis. Hepatology 1991; 13: 455-9.
20. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996; 23: 1025-9.
21. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111: 473-8.
22. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193-7.
23. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
24. Adler M, Shaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811-6.
25. Cortez-Pinto E, Baptista A, Camilo ME, et al. Non-alcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-9.
26. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-5.
27. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
28. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
29. Letterson P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
30. Jaeschke H, Wang Y, Essani NA. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation [Abstract]. Hepatology 1996; 24: 238A.
31. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultures of heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417-26.
32. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
33. Weltman MD, Farrel GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
34. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-48.
35. Pappo I, Bacovier H, Berry EM, et al. Polimixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat. J Surg Res 1991; 51: 106-12.
36. Freud HR, Muggia-Sullan M, LaFrance R, et al. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements. J Surg Res 1985; 38: 356-3.
37. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-62.
38. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-700.
39. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatoheaptitis. A pilot study. J Am Med Assoc 1999; 282: 1659-64.
40. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
41. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
42. Boncovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
43. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
44. Andersen T, Gludd C, Franzmann MB, Christofferesen P. Hepatic effect of dietary weight loss in morbidly obese patients. J Hepatol 1991; 12: 224-9.
45. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
46. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83-8.
47. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
48. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
49. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. A persistent aminotransferasemia resolving after weight reduction of children. J Pediatr 1994; 125: 239-41.
50. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
51. Drenik EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829-34.
52. Kanders BS, Blackburn GL. Very-low calorie diets for the treatment of obesity. In: Blackburn GL, Kanders BS. eds. Obesity: Pathophysiology. Psychology and Treatment. New York: Chapman & Hall, 1994: 197-215.
53. Kolanowski J. A risk benefit assessment of anti-obesity drugs. Drug Safety 1999; 20: 119-31.
54. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16.
55. DeWind LT, Payne JH. Intestinal bypass surgery for morbid obesity. Long term results. J Am Med Assoc 1976; 236: 2298-301.
56. Campbell JM, Hung TK, Karam JH, et al. Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977; 137: 602-10.
57. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
58. Besaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with non-alcoholic steatohepatitis. J Hepatol 1999; 31: 384.
59. Caldwell SH, Hespenheiden EE, Redick JA, et al. A pilot study of thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
60. Watkins PB, Whitcomb RW, Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 908-9.
61. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nature Med 2000; 6: 998-1003.
62. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
63. Quigley EM, Marsch MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104: 286-301.
64. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132: 525-32.
65. Buchman AL, Dubin MD, Mourkarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995; 22: 1390-403.
66. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in longterm total parenteral nutrition. Gastroenterology 1992; 102: 1363-70.
67. Fleming CR. Hepatobiliary complications in adults receiving nutrition support. Dig Dis 1994; 12: 191-8.
68. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial [Abstract]. Hepatology 1998; 26: 387A.
69. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 1998; 28: 386A.
70. Holoman J, Glasa J, Kasar J, et al. Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy. J Hepatol 2000; 32: 210.
71. Barak AJ, Beckenhauer HC, Junnila M, et al. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993; 17: 552-5.
72. Abdelmalek M, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-7.
73. Gulbahar O, Karasu ZA, Ersoz G, et al. Treatment on nonalcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000; 118: A1444(Abstract).
74. Lavine JE, Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
75. Hasewaga T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic hepatitis; a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
76. Desai TK, Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2000; 118: A975(Abstract).
77. Nitecki J, Jackson FW, Allen ML, et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [Abstract]. Gastroenterology 2000; 118: A1474(Abstract).
78. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 1802-5.
79. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for criptogenic cirrhosis. Liver Transpl 2001; 7: 363-73.
80. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-14.